Quick Answer
NovoCure Ltd reported R&D Expense of $224.54 million for fiscal year 2025.
NovoCure Ltd R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $224.54M | +7.1% |
| 2024 | $209.65M | -6.0% |
| 2023 | $223.06M | +8.2% |
| 2022 | $206.09M | +2.4% |
| 2021 | $201.30M | +52.5% |
| 2020 | $132.01M | +67.1% |
| 2019 | $79.00M | +56.2% |
| 2018 | $50.57M | +32.7% |
| 2017 | $38.10M | -8.1% |
| 2016 | $41.47M | -5.2% |
| 2015 | $43.75M | +8.3% |
| 2014 | $40.38M | +16.0% |
| 2013 | $34.80M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $54.03M | +4.1% | -3.2% |
| June 30, 2025 | $55.83M | +1.6% | +3.8% |
| March 31, 2025 | $53.78M | +4.2% | +3.7% |
| September 30, 2024 | $51.88M | -3.2% | -5.6% |
| June 30, 2024 | $54.95M | -0.9% | +6.5% |
| March 31, 2024 | $51.60M | -13.6% | -3.8% |
| September 30, 2023 | $53.62M | +3.2% | -3.3% |
| June 30, 2023 | $55.43M | -2.9% | -7.2% |
- NovoCure Ltd showed an increase of +7.1% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, NovoCure Ltd’s r&d expense has grown by 545.3% (from $34.80 million to $224.54 million).
- The most recent figure is from NovoCure Ltd’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: